Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. - Wikidata - wikimedia - TriplyDB

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.

http://www.wikidata.org/entity/Q38088261

about

Urinary tract infections: epidemiology, mechanisms of infection and treatment options Modulation of Membrane Influx and Efflux in Escherichia coli Sequence Type 131 Has an Impact on Bacterial Motility, Biofilm Formation, and Virulence in a Caenorhabditis elegans Model Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: an analysis of national representative claims database Development of a panel of recombinase polymerase amplification assays for detection of common bacterial urinary tract infection pathogens.Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013.Molecular Characterisation of nfsA Gene in Nitrofurantoin Resistant Uropathogens.Stress responses as determinants of antimicrobial resistance in Pseudomonas aeruginosa: multidrug efflux and more.AcrB-AcrA Fusion Proteins That Act as Multidrug Efflux Transporters.Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates.Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.Local drug delivery in the urinary tract: current challenges and opportunities.

P2860

Q27022487-8959A2E0-AB69-4401-9626-2AB2D727BB0F Q30385057-FE969C92-6341-41E9-9F68-08B22704E602 Q36153920-BA9E7A44-DDCA-4414-B7F5-A04C1EBE1222 Q36373340-4C3D9252-4514-4D83-A844-8B7D7591EB04 Q36683599-C7D151B0-B046-48CA-855B-30284CF40873 Q37119884-BE1E92BF-B51D-4A8E-B291-13F0A321117F Q37132442-F01DC97C-5C71-43CC-A9C3-369760F05FEE Q38267242-0FF9C770-7337-43C5-9AEC-B64155947943 Q38385964-1FF2DB6B-830A-4956-BD38-18489FEFC9C7 Q39905753-32578E87-B6F3-412A-8035-671B6357E6E0 Q40976615-8885A7D4-D2C8-40C2-B95F-4E34ABBAF11E Q41281692-2F9901B2-8811-41CB-94D8-CE1A4943C5D0 Q49685896-77478C08-E634-4DCC-BDDA-2021B67D8E83

P2860

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections.

http://www.wikidata.org/entity/Q38088261

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging resistance problems a ...... ated urinary tract infections.

@en

type

label

Emerging resistance problems a ...... ated urinary tract infections.

@en

prefLabel

Emerging resistance problems a ...... ated urinary tract infections.

@en

P1433

Q38088261-949F24AE-A0B3-45F7-ACBD-949010D23630

P1476

Q38088261-923F1A17-478B-47E7-95D1-7D0AFA2AA539

P2093

Q38088261-0D4CC35F-FA55-4F12-B9F1-E2EF4273F20F

Q38088261-30631E0B-ADE7-48A4-AA9D-AFD08EBDA1F2

P2860

Q38088261-026295AB-4E0D-4E78-88DF-C4FEFB9F1CEF

Q38088261-02ED4B2A-EB71-470E-B293-EA80796C20FA

Q38088261-04041ED8-2C33-498A-8266-4E793632A0B1

Q38088261-098AA0F9-D1B2-445E-AA40-FF7FB65521FC

Q38088261-17A99C72-D6BC-46C6-9D76-26D5921E7F53

Q38088261-18FF50D0-F865-4560-8AED-CA3AF76110EC

Q38088261-1FAC532D-712B-4F9F-9E51-7271C08D11D1

Q38088261-232D7D6F-483E-4028-83D5-D99AFE2C5B17

Q38088261-265FC831-45D5-4350-AFD5-A0BEBE78EB06

Q38088261-275890E7-1552-4612-8A92-02697B404532

P304

Q38088261-1B563143-9A65-4EDF-AEAA-3C7BBAA632B2

P31

Q38088261-E48C5C2B-737F-429C-9BFD-5E03DEC16C83

P356

Q38088261-A4439EE6-4658-4FD4-BC7F-3F9668342F37

P407

Q38088261-82551D81-BA11-4767-ACBA-4F3AE8551F96

P433

Q38088261-36225851-AF91-478F-8D6F-26544E3DEB8F

P478

Q38088261-72A1E5F0-863E-496A-98FF-4DE0D4B3F4BF

P50

Q38088261-5BC41CF0-D746-47D4-AF2C-37F44CD60D33

P577

Q38088261-F4014A8F-29AE-4851-B57B-6CE5AFED83F6

P698

Q38088261-04197B88-BE27-44F4-963A-2A5E9483EA79

P921

Q38088261-2BFD2CE4-C8D7-4FE5-91BB-9D1A16EA6C1D

P356

14656566.2013.778827

P1433

Expert Opinion on Pharmacotherapy

P1476

Emerging resistance problems a ...... ated urinary tract infections.

@en

P2093

Wen-Chien Ko

http://www.w3.org/2001/XMLSchema#string

Yen-Hsu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci

Pseudomonas aeruginosa: all roads lead to resistance

Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America

Management of multidrug-resistant enterococcal infections

International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies.

P304

587-596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.778827

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23480061

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy